The short answer
Semaglutide does not establish a routine need for chromium. Oral chromium should fit around semaglutide-tablet administration instructions; injected semaglutide does not require the same gap.
What this answer covers
Chromium supplements, not an established deficiency diagnosis; oral versus injected semaglutide.
- Supplement or preparation
- Chromium
- Medication ingredient
- semaglutide
No replacement requirement is established
The semaglutide labels do not establish chromium depletion or a chromium-replacement regimen. A change in appetite or glucose control does not by itself diagnose a mineral deficiency.
Tablet timing differs from injection timing
Take a semaglutide tablet on an empty stomach in the morning with up to 4 ounces of plain water. Wait at least 30 minutes before food, drinks or another oral product, including a supplement. Weekly injections do not have this fasting or 30-minute rule.
Why tablets are taken alone
In a healthy-participant study, five placebo tablets taken with oral semaglutide reduced semaglutide exposure. Chromium was not studied, so the result cannot predict a chromium-specific percentage change.
Review the whole supplement plan
Discuss why chromium is being used and follow the prescribed glucose-monitoring plan. Do not add chromium automatically, change semaglutide yourself, or assume that spacing makes a glucose-lowering supplement risk-free.
Evidence and practical considerations
Timing & monitoring
Conditional oral-tablet timing supported by current exact labels and co-tablet pharmacokinetic study; no increased supplement need, universal avoidance or injection gap established.
- Exact scope
- Chromium supplements, not an established deficiency diagnosis; oral versus injected semaglutide. with Semaglutide RxCUI 1991302 IN; exact oral-tablet and subcutaneous formulation boundaries.
- Medication form and route
- oral medication; subcutaneous medication; oral supplement
What remains uncertain
- No supplement-specific percentage, event rate, nutrient requirement or injection gap established.
Factors that may matter: Formulation; Preparation; Insulin or sulfonylurea co-use; Gastrointestinal symptoms.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact semaglutide article distinguishing oral administration, injected treatment and supplement-specific evidence. | |
| Research summary published |
Article revision: a3263b4745b6dbaf
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.